Atypical Antipsychotics - MGH Center for Women's Mental Health

New Research from the CWMH: More Data on the Reproductive Safety of Lurasidone and Quetiapine

New findings from the National Pregnancy Registry for Atypical Antipsychotics provide reassuring data regarding the safety of prenatal exposure to lurasidone and quetiapine in a sample of well-characterized participants.

By MGH Center for Women's Mental Health|2023-04-24T17:05:19-04:00April 25th, 2023|Atypical Antipsychotics, Medications and Pregnancy, New Research|0 Comments

New Research from the CWMH: No Increase in Major Malformations in Children with Prenatal Exposure to Olanzapine

No major malformations were associated with olanzapine exposure during the first trimester of pregnancy.

By MGH Center for Women's Mental Health|2023-03-02T15:52:24-04:00March 1st, 2023|Atypical Antipsychotics, New Research|0 Comments

Accumulating Data on the Reproductive Safety of Second-Generation Antipsychotics, But Still Not Enough

In a cohort of 351 children exposed to second generation antipsychotic during pregnancy, the risk of major congenital malformations did not differ from a comparison group of non-exposed children.

By MGH Center for Women's Mental Health|2022-12-08T18:32:09-04:00June 21st, 2022|Atypical Antipsychotics, Psychiatric Disorders During Pregnancy|0 Comments